康恩贝子公司盐酸丙卡特罗吸入溶液获得药品注册证书

Core Viewpoint - Kang En Bei (600572) has received approval from the National Medical Products Administration for two specifications of the inhalation solution of Salbutamol Hydrochloride, indicating a significant advancement in its product portfolio and potential market opportunities in the respiratory medication sector [1] Group 1: Company Developments - Kang En Bei's wholly-owned subsidiary, Zhejiang Jinhua Kang En Bei Biopharmaceutical Co., Ltd., has been granted drug registration certificates for Salbutamol Hydrochloride inhalation solution with approval numbers H20256396 and H20256397 [1] - The inhalation solution was first launched in Japan in 2002 under the brand name "Meptin" [1] Group 2: Product Information - The approved specifications for the inhalation solution are 0.5ml:50μg and 0.3ml:30μg, which are set to be marketed in China in 2023 and 2024 respectively [1] - The primary indications for the inhalation solution include alleviating symptoms of bronchial asthma, chronic bronchitis, and emphysema, which are diseases characterized by airflow limitation [1]